

IPTL





10-10-2005

OCT 1 0 2005

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:

4115-148

Applicant:

Redfield, et al.

Application No.:

10/527,904

9067

Date Filed:

March 14, 2005

Customer No.:

Docket No.:

Conf. No.:

Title:

COMPOSITIONS FOR

INDUCING INCREASED

LEVELS OF B-CHEMOKINES

AND METHODS OF USE

THEREFOR

23448

FACSIMILE TRANSMISSION CERTIFICATE

Fax No.: (571) 273-8300

I hereby certify that this document is being filed in the United States Patent and Trademark Office, via facsimile transmission to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on October 10, 2005, to United States Patent and Trademark Office facsimile transmission number (571) 273-8300.

Marianne Fuierer

No. of Pages

October 10, 2005 Date

RESPONSE TO AUGUST 15, 2005 NOTICE TO COMPLY IN U.S. PATENT APPLICATION NO. 10/527,904

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants were sent the enclosed "Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosure." However, there are no sequence listings in the above-identified application. Applicants request that the Office recognize

this fact and if in disagreement point out specifically where in the application these sequence listings are recited.

Applicants have completed all necessary requirements under 35 USC §371 for acceptance of this application and request that the Office acknowledge same.

Respectfully submitted,

Marianne Fuierer

Attorney for the Applicants Registration No. 39,983

INTELLECTUAL PROPERTY/ TECHNOLOGY LAW Telephone: (919) 419-9350 Facsimile: (919) 419-9354 IPTL File: 4115-148

7

09/13/2002



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE UNITED STATES DEFARTMENT OF COMM United States Patient and Tradermark Office Addrew COMMISSIONER FOR PATENTS Alexandria, Vignus 22313-1450 www.usphugov

09/12/2003

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO. 10/527,904 Robert R Redfield 4115-148

INTERNATIONAL APPLICATION NO.

PCT/US03/28697 I.A. FILING DATE PRIORITY DATE

23448 INTELLECTUAL PROPERTY / TECHNOLOGY LAW PO BOX 14329 RESEARCH TRIANGLE PARK, NC 27709

AUG 1 9 2005

CONFIRMATION NO. 9067 371 FORMALITIES LETTER *OC000000016602303*

OC000000016802303

Date Mailed: 08/15/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
10/527,904	PCT/US03/28697	4115-148

FORM PCT/DO/EO/922 (371 Formalities Notice)